title: [Efficacy of regional administration of urokinase and argatroban via small saphenous vein catheter for treatment of acute deep venous thrombosis in the lower limb].
abstract: OBJECTIVE
  To investigate the clinical value of local regional administration of urokinase and argatroban through small saphenous vein (SSV) catheter in the treatment of acute deep venous thrombosis in the lower limb (LDVT).
  
  
  METHODS
  Fifty-six patients with acute LDVT were prospectively randomized into the study group (21 cases, 24 limbs) and control group (35 cases, 36 limbs) for treatment with urokinase and argatroban regionally administered via the SSV catheter and with the same agents given via the peripheral vein, respectively. The patients were examined for changes in serum fibrinogen (FBG) and D-dimer and the perimeter of the affected limbs, and the complications in relation to the agents were observed.
  
  
  RESULTS
  By corrected Chi-square test, the incidence of complications was significantly lower in the study group than in the control group (1/21 vs 4/36, χ(2)=1.92, P≤0.05). Wilcoxon's sign rank test suggested no statistically significant difference between the two groups in the total effective rate (95.8% vs 94.4%, V=0.52, P>0.05), but the total excellent rate differed significantly between them (83.3% vs 55.6%, V=2.36, P≤0.05). Serum FBG underwent no significant variations in the study group during thrombolysis (P>0.05), but decreased significantly in the control group (P≤0.05). The decreases in serum D-dimer and perimeter of the affected limbs occurred earlier in the study group than in the control group (P≤0.05).
  
  
  CONCLUSIONS
  Regional administration of urokinase and argatroban via small saphenous vein catheter can promote the thrombolytic effect and reduce the risk of hemorrhage in the treatment of LDVT.
authors.affiliation: Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. zhoujohnson001@yahoo.com.cn
authors.forename: Zhong-xin
authors.initials: ZX
authors.lastname: ZHOU
authors.forename: Chun-qiu
authors.initials: CQ
authors.lastname: PAN
authors.forename: Fang-yong
authors.initials: FY
authors.lastname: FU
authors.forename: Zhi-qi
authors.initials: ZQ
authors.lastname: LIN
authors.forename: Zheng-jun
authors.initials: ZJ
authors.lastname: LIU
mesh_terms: D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives; D005260:Female; D005343:Fibrinolytic Agents; D006801:Humans; D007275:Injections, Intravenous; D035002:Lower Extremity / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D010875:Pipecolic Acids / Q000008:administration & dosage* / Q000627:therapeutic use; D012501:Saphenous Vein; D013449:Sulfonamides; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D005343:Fibrinolytic Agents; D010875:Pipecolic Acids; D013449:Sulfonamides; D001120:Arginine; D014568:Urokinase-Type Plasminogen Activator; C031942:argatroban